LC
ABBV icon

Lindbrook Capital’s AbbVie ABBV Stock Holding History

Lindbrook Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$2.56M Buy
12,237
+848
+7% +$165K 0.24% 65
2024
Q4 		$2.02M Sell
11,389
-110
-1% -$20.2K 0.18% 75
2024
Q3 		$2.27M Buy
11,499
+265
+2% +$49.5K 0.2% 71
2024
Q2 		$1.93M Buy
11,234
+751
+7% +$124K 0.18% 81
2024
Q1 		$1.91M Buy
10,483
+689
+7% +$119K 0.18% 80
2023
Q4 		$1.52M Buy
9,794
+591
+6% +$86.2K 0.15% 88
2023
Q3 		$1.37M Buy
9,203
+629
+7% +$92.3K 0.15% 90
2023
Q2 		$1.16M Sell
8,574
-1,781
-17% -$261K 0.12% 105
2023
Q1 		$1.65M Sell
10,355
-253
-2% -$38.7K 0.19% 77
2022
Q4 		$1.71M Buy
10,608
+944
+10% +$145K 0.21% 77
2022
Q3 		$1.3M Buy
9,664
+1,239
+15% +$178K 0.22% 60
2022
Q2 		$1.29M Buy
8,425
+163
+2% +$24.9K 0.21% 61
2022
Q1 		$1.34M Sell
8,262
-295
-3% -$42.9K 0.21% 68
2021
Q4 		$1.16M Buy
8,557
+4,077
+91% +$482K 0.18% 71
2021
Q3 		$483K Hold
4,480
– – 0.13% 72
2021
Q2 		$505K Sell
4,480
-904
-17% -$102K 0.11% 76
2021
Q1 		$583K Buy
5,384
+114
+2% +$12.2K 0.13% 62
2020
Q4 		$565K Buy
5,270
+653
+14% +$62.8K 0.14% 57
2020
Q3 		$404K Sell
4,617
-39
-0.8% -$3.67K 0.11% 75
2020
Q2 		$457K Buy
4,656
+429
+10% +$37.8K 0.14% 56
2020
Q1 		$322K Sell
4,227
-673
-14% -$57.3K 0.12% 71
2019
Q4 		$434K Buy
4,900
+153
+3% +$12.7K 0.15% 69
2019
Q3 		$359K Buy
4,747
+214
+5% +$14.7K 0.14% 74
2019
Q2 		$329K Sell
4,533
-312
-6% -$24.5K 0.13% 81
2019
Q1 		$390K Buy
4,845
+965
+25% +$78.9K 0.16% 66
2018
Q4 		$357K Buy
+3,880
New +$341K 0.18% 61

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Lindbrook Capital's ABBV Position: Q1 2025 in Review

Lindbrook Capital increased its AbbVie (ABBV) stake by 7.4% in Q1 2025, buying an estimated $165K and bringing the position to 12,237 shares worth $2.56M. The position accounts for 0.24% of the portfolio, ranked #65.

Lindbrook Capital first reported a position in ABBV in Q4 2018 and has held it in 26 quarters since. 3,820 funds tracked by Wall St. Rank hold ABBV as of Q1 2025.

  • Lindbrook Capital held 12,237 shares of AbbVie worth $2.56M as of Q1 2025.
  • Lindbrook Capital bought 848 AbbVie shares in Q1 2025, an estimated $165K.
  • AbbVie made up 0.24% of Lindbrook Capital's portfolio in Q1 2025, its #65 holding.
  • Lindbrook Capital first reported a position in AbbVie in Q4 2018 and has held it in 26 quarters since.
  • 3,820 funds tracked by Wall St. Rank held AbbVie as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.